We’ve seen how government subsidies and supports for the manufacturing process can speed distribution exponentially. And we’ve seen that when the government makes a life-saving 処理 free for all who need it, you can get more than 220 million vaccines into arms in fewer than 100 日々.
If we’re going to solve the cancer crisis, not just on an individual basis, but on a global scale, we need to treat it with the same urgency and resolve we treated COVID-19（新型コロナウイルス感染症.
And there’s no reason why we shouldn’t. Cancer is a pandemic too, even if it isn’t infectious. 昨年, it killed nearly 10 百万人, more than three times as many people as the coronavirus. And it will again this year and next year and the year after that – unless we do something big.
While it’s a national issue, it’s also personal for me; 2021 marks 25 years since I was first diagnosed with multiple myeloma, a rare and incurable blood cancer. It also marks 22 years since I was supposed to die.
When I was first diagnosed, there were no treatments for the disease. Nor was there a research foundation dedicated to finding them. I was lucky – and endlessly grateful – that new breakthroughs were there in time to save my life. I know that each year since has been an extraordinary gift. But I know, あまりにも, that my experience remains far too rare.
Cancer patients are often haunted by a petrifying kind of terror that I experienced myself: knowing there may be a new treatment just around the corner, but that you may not survive to see it. Slowness is the cruelest of enemies when you’re running out of time.
もちろん, there are a great many reasons to be hopeful about the future.
In the past two years, the FDA has approved more than 30 cancer drugs. If you’re a cancer patient trying to google your way to answers, you’ll read headlines that herald a new era in precision medicine that has been supercharged by genomic advances. New frontiers in immunotherapies have opened, as have new technologies like CRISPR.
There’s even an effort by the companies that developed the mRNA vaccines to leverage that same technology to develop cancer vaccines.
But this progress belies a foundational problem in our battle against cancer. The time between discovery of a new therapy and distribution at scale is painfully, unacceptably long.
I’ll never forget the experience when a friend of mine got herself into the first clinical trial for CAR T-cell therapy (CAR-T) for multiple myeloma. When I said goodbye to her, she weighed about 90 ポンド, and I felt a foreboding sense that she would surely die. それでもまだ, by a miracle, she went into remission – and stayed there. She gave an interview to a magazine sharing that CAR-T had cured her.